Subretinal Fibrosis / wet AMD Treatment
OLX301D is designed to target CTGF mRNA and inhibit the progression of subretinal fibrosis and neovascularization.
Many times, subretinal fibrosis is the direct cause of vision loss. As there are no approved drugs and the therapeutics is expected to,
be effective in approximately 30% of wet AMD patients who do not respond to anti-VEGF treatments,
the program is expected to address a significant portion of unmet needs once developed.
* CTGF(Connective Tissue Growth Factor): a protein regulating proliferation and tissue repair
* VEGF(Vascular Endothelial Growth Factor): a signal protein stimulating the formation of new blood vessels
Target RNA: CTGF
Administration Route: Intravitreal Injection
Subretinal Fibrosis (SRF)
Subretinal fibrosis, which occurs in most cases of wet AMD, is known as the leading cause of irreversible vision loss. During neovascularization, fibrosis occurs along with local destruction of the RPE and choroidal vessels, permanently impairing the macula.
- Expanded License and Collaboration Agreement with Théa Open Innovation (Territory: Worldwide excl. Asia-Pacific) (20.10)
- Efficacy identified in animal models with SRF and wet AMD
- Confirmation of superior synergistic efficacy with conventional anti-VEGF treatment
- 2021 CSHL(Cold Spring Harbor Laboratory)-Nucleic Acid Therapies (21.03)
- 2021 OTS (Oligonucleotide Therapeutics Society) (21.09)